Bolt Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.8M
- Price
- $3.67
- % Change (Daily % change from the live per-ticker quote feed.)
- +14.61%
- Volume
- 65.3K
About
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Quick stats
Shares outstanding1.9M
Computed float1.4M
Float / shares71.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001641281
Websitehttps://www.boltbio.com
AI Summary
AI-generated1/8
minorbullishticker change
Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle
Bolt Metals Corp. will rebrand as 26 Metals Inc. and trade under the ticker symbol IRON on the CSE effective August 19, 2026.
The strategic pivot focuses the company on its flagship Florália Iron Project in Brazil's Iron Quadrangle, targeting a sinter-feed product grading above 61% Fe with a dry processing flowsheet.
The company also appointed Rob Saltsman to the board and confirmed a definitive option agreement to acquire a 100% interest in the Florália property.